CN103230478B - Selenium-rich natto product - Google Patents
Selenium-rich natto product Download PDFInfo
- Publication number
- CN103230478B CN103230478B CN201310158684.3A CN201310158684A CN103230478B CN 103230478 B CN103230478 B CN 103230478B CN 201310158684 A CN201310158684 A CN 201310158684A CN 103230478 B CN103230478 B CN 103230478B
- Authority
- CN
- China
- Prior art keywords
- rich selenium
- powder
- natto
- selenium
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011669 selenium Substances 0.000 title claims abstract description 194
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 194
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 185
- 235000013557 nattō Nutrition 0.000 title claims abstract description 148
- 239000000843 powder Substances 0.000 claims abstract description 88
- 229940094952 green tea extract Drugs 0.000 claims abstract description 26
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 26
- 229940086319 nattokinase Drugs 0.000 claims abstract description 18
- 108010073682 nattokinase Proteins 0.000 claims abstract description 18
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 15
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 10
- 229950001002 cianidanol Drugs 0.000 claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 9
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 108010074686 Selenoproteins Proteins 0.000 claims description 10
- 102000008114 Selenoproteins Human genes 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000005487 catechin Nutrition 0.000 claims description 9
- 229920001282 polysaccharide Polymers 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- -1 selenium polysaccharide Chemical class 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- CAXNYFPECZCGFK-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylacetonitrile Chemical compound C=1C=CC=NC=1C(C#N)C1=CC=CC=C1 CAXNYFPECZCGFK-UHFFFAOYSA-N 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000010439 isomalt Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims description 2
- 239000003651 drinking water Substances 0.000 claims description 2
- 235000020188 drinking water Nutrition 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 27
- 208000007536 Thrombosis Diseases 0.000 abstract description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 235000012000 cholesterol Nutrition 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 4
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 2
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- 230000001906 cholesterol absorption Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000002792 vascular Effects 0.000 description 11
- 238000001514 detection method Methods 0.000 description 8
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 7
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 7
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 229960001913 mecysteine Drugs 0.000 description 7
- 229960002718 selenomethionine Drugs 0.000 description 7
- 239000007910 chewable tablet Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003346 selenoethers Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- BUGBHKTXTAQXES-AHCXROLUSA-N Selenium-75 Chemical compound [75Se] BUGBHKTXTAQXES-AHCXROLUSA-N 0.000 description 1
- BNSWSSGKYAJNRB-RGMNGODLSA-N [Se].C(CC)N[C@@H](CCO)C(=O)O Chemical compound [Se].C(CC)N[C@@H](CCO)C(=O)O BNSWSSGKYAJNRB-RGMNGODLSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- BUGBHKTXTAQXES-DBXDQKISSA-N selenium-70 Chemical compound [70Se] BUGBHKTXTAQXES-DBXDQKISSA-N 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
Abstract
The invention discloses a selenium-rich natto product, which comprises the following components in parts by weight: 35-50 parts of selenium-rich natto powder, 10-16 parts of phytosterol powder and 10-15 parts of green tea extract powder. The selenium-rich natto powder contains selenium natto kinase with high activity and long lasting time, and organic selenium, thus having an excellent antioxidation effect; phytosterol contained in the phytosterol powder has the effects of inhibiting cholesterol absorption of a human body, promoting katabolism of cholesterol, inhibiting biochemical synthesis of the cholesterol and the like; and catechinic acid contained in the green tea extract powder has the effects of inhibiting blood pressure and blood sugar, reducing cholesterol and low density lipoprotein in blood and increasing the content of high density lipoprotein. According to the selenium-rich natto product, the selenium-rich natto powder, the phytosterol powder and the green tea extract powder are combined in scientific proportion to take effect together in three aspects of inhibiting thrombus formation, improving thrombus dissolution and enhancing the toughness of blood vessels, and therefore, the selenium-rich natto product is capable of effectively preventing cardiovascular and cerebrovascular diseases.
Description
Technical field
The open one of the present invention is used for thrombus, prevents thrombotic natto product, especially a kind of rich selenium natto product that is rich in selenium Nattokinase and Organic Selenium.
Background technology
At present, China's cardiovascular and cerebrovascular thrombotic disease is one of the most serious and modal disease of the middle-aged and old health of harm.According to statistics, there are thrombotic diseases patient approximately 1,500 ten thousand people in the whole world, wherein dies from every year cardiovascular and cerebrovascular thrombotic disease approximately 1,200 ten thousand people.In China, patient with cerebral apoplexy leave hospital after the recurrence rate of First Year be that the recurrence rate of 30%, the five year is up to 59%.Because China is populous, pace of population aging accelerates, so effectively preventing cardiovascular and cerebrovascular thrombotic disease is significant.Although current existing treatment thrombus medicine is obtained significant effect, having some limitations property, such as anticoagulant and antiplatelet drug have certain side effect, and cannot thrombus main matter insoluble fibrin.Thrombolytic drug oral administration is invalid, can only be used for injection, and ID is excessive may cause massive haemorrhage in body, and it is very careful to need.In addition, it is very short at people's Half-life in vivo, and therefore onset time is very short.And some Chinese medicines, such as ginkgo, the red sage root, pseudo-ginseng, leech etc., cannot thrombus main matter insoluble fibrin, be mainly to play the effect that regulates blood fat.
Nattokinase is proved to be effectively thrombus, is mainly effectively to dissolve insoluble fibrin, and this albumen is the important substance of composition vascular wall patch.But the activity of the Nattokinase of traditional natto product is lower, be 1000FU/g, the duration is short, and thrombolytic effect is limited.At present, the selenium in the natto product of rich selenium or the product of other thrombus dissolvings is all generally selenide of carragheen, or inorganic selenium; the absorption rate of selenium is limited; and the selenium oxidation resistant active principle that is blood vessel can strengthen vascular toughness, protection blood vessel is not subject to radical damage.Cholesterol, low-density lipoprotein are all the materials that strengthens blood viscosity, causes disorders of lipid metabolism, and lipid material, in vascular wall inner membrance deposition, forms little " patch " gradually, medically becomes " atherosclerotic ".These patches increase, increase, and artery-clogging gradually causes blood vessel official jargon narrow, and blood circulation is not smooth, if vitals artery blood supply insufficiency will cause serious consequence.Conventionally serious is cardiovascular and cerebrovascular atherosclerotic, can cause coronary heart disease, miocardial infarction, angina pectoris, cerebral thrombus, cerebral hemorrhage, apoplexy etc., even threat to life.Existing product is not taken into account three aspects such as thrombus, anti-oxidant softening blood vessel, reduction thrombosis desired substance simultaneously, and thrombolytic natto kinase activity is low, and action time is not lasting, and the effect of therefore preventing and treating cardiovascular and cerebrovascular disease is restricted.
Summary of the invention
The object of the invention is to overcome the deficiencies in the prior art part and provide a kind of can be from suppressing thrombosis, increase thrombus dissolving, strengthen the acting in conjunction of vascular toughness three aspects:, the rich selenium natto product that effectively prevents cardiovascular and cerebrovascular disease to occur; In addition, the present invention also provides the purposes of described rich selenium natto product in the medicine for the preparation of prevention or treatment cardiovascular and cerebrovascular disease.
For achieving the above object, the technical scheme that the present invention takes is: a kind of rich selenium natto product, the component that comprises following weight portion: 35～50 parts of rich selenium natto powders, 10～16 parts, phytosterol powder, 10～15 parts, green-tea extract powder.
In rich selenium natto powder described above, contain selenium Nattokinase, it is the bond of selenium and Nattokinase, its enzymatic activity can reach 2000～2500FU/g, compared with the Nattokinase that is 1000FU/g with existing conventional activity, have advantages of that activity is high, the duration is long, can more effective thrombus.In addition, in described rich selenium natto powder, contain selenoprotein and selenium propylhomoserin, bioavailability is good, and safety.Albumen selenium is that one has bioactive material, selenium and protein combination have anti-oxidant synergy, antioxidation is fabulous, use together with selenium Nadou enzyme solution, also there is the effect of effect each other of mutually promoting, be mainly manifested in anti-oxidant, to strengthen vascular wall toughness, remove the residue of blood vessel simultaneously.The effects such as phytosterol has stronger antiinflammatory action to human body, and the biochemistry that have the katabolism that can suppress the absorption of human body to cholesterol, promote cholesterol, suppresses cholesterol is synthetic.Catechin has inhibition blood pressure (can reduce diastolic pressure and systolic pressure) and blood sugar (suppressing candy amylase), reduces blood cholesterol and low-density lipoprotein, and increases the amount of HDL.Rich selenium natto product of the present invention, the materials such as rich selenium natto powder, phytosterol powder, green-tea extract powder are combined together according to the ratio of science, from suppressing the formation of thrombus, the dissolving that increases thrombus, the acting in conjunction of enhancing vascular toughness three aspects:, effectively prevent the generation of cardiovascular and cerebrovascular disease.
As the preferred embodiment of rich selenium natto product of the present invention, the component that described rich selenium natto product comprises following weight portion: 35～45 parts of rich selenium natto powders, 12～15 parts, phytosterol powder, 11～15 parts, green-tea extract powder.As the more preferably embodiment of rich selenium natto product of the present invention, the component that described rich selenium natto product comprises following weight portion: 36～38 parts of rich selenium natto powders, 13～14 parts, phytosterol powder, 12～13 parts, green-tea extract powder.
As the preferred embodiment of rich selenium natto product of the present invention, described rich selenium natto product also comprises the auxiliary material of 32～35 weight portions.As the more preferably embodiment of rich selenium natto product of the present invention, described auxiliary material comprises at least one in soybean lecithin, isomalt, starch, mannitol, lactose, dolomol.
As the preferred embodiment of rich selenium natto product of the present invention, described rich selenium natto powder adopts following methods to be prepared from:
(1) actication of culture: activation medium is containing yeast extract, peptone, dipotassium hydrogen phosphate, sodium chloride, agar and distilled water, the pH of activation medium is 7.0～7.5, by culture medium at 119～121 DEG C after sterilizing 30min, inoculation bafillus natto, and be, at 36～38 DEG C, bafillus natto is activated to 24h in temperature;
(2) bacterial classification expands cultivation: the culture medium that bacterial classification expands contains peptone, glucose, dipotassium hydrogen phosphate, magnesium sulfate, calcium chloride and distilled water, the pH of culture medium is 7.0～7.5, by culture medium sterilizing 30min at 119～121 DEG C, be then at 36～38 DEG C, to expand to cultivate 24h by the bafillus natto after activation in temperature;
(3) fermentation: Drinking Water is heated to 50～60 DEG C, add rich selenium soyabean protein powder according to 10～15% of the water yield, fully stir and form rich selenium soyabean protein powder suspension, then in rich selenium soyabean protein powder suspension, add dipotassium hydrogen phosphate, regulating pH is 7.0～7.5, cooling after sterilizing 30min at 119～121 DEG C, add step (2) to expand the bafillus natto after cultivating, at 36～38 DEG C of bottom fermentation 48h;
(4) zymotic fluid after step (3) fermentation is suppressed to bafillus natto at 80～85 DEG C of deactivation 35min(), after then at 60～70 DEG C, vacuum drying to solid content is 30%, freeze drying, obtains rich selenium natto powder.
As the preferred embodiment of rich selenium natto product of the present invention, in described rich selenium natto powder, contain Organic Selenium 50～87.5 μ g/g, selenium Nattokinase 2000～2500FU/g; In described phytosterol powder, contain phytosterol 100～125mg/g; In described green-tea extract powder, contain catechin 100～125mg/g.As the more preferably embodiment of rich selenium natto product of the present invention, described Organic Selenium is selenoprotein, selenoaminoacid, selenium polysaccharide.In rich selenium natto product of the present invention, Organic Selenium mainly exists with the form of natural selenoprotein, selenoaminoacid, as selenomethionine, seleno methyl cysteine, a small amount of is natural selenium polysaccharide, compared with generally existing with the form of selenide of carragheen or inorganic selenium with the selenium in existing product, have that bioavailability is good, safety and the advantage such as antioxidation is good.
As the preferred embodiment of rich selenium natto product of the present invention, described rich selenium natto product is tablet, capsule or pulvis.Rich selenium natto product of the present invention, can coordinate auxiliary material to be made into tablet, capsule or pulvis solid beverage etc., can select suitable formulation to take according to the hobby of different crowds or different people.
In addition, the present invention also provides the purposes of rich selenium natto product described above in the medicine for the preparation of prevention or treatment cardiovascular and cerebrovascular disease.
Rich selenium natto product of the present invention, described rich selenium natto powder contains selenium Nattokinase and Organic Selenium, and the activity of selenium Nattokinase is up to 2000～2500FU/g, and activity is high and the duration is long, and thrombolytic effect is good; Organic Selenium has antioxidation, improves vascular wall toughness.Described phytosterol has the effect that reduces blood cholesterol levels, reduces the formation of thrombus, and the heart disease of prevention and treatment coronary atherosclerosis class is had to good effect.Described green-tea extract has the effect that suppresses low-density lipoprotein content in blood.Rich selenium natto product of the present invention, the materials such as rich selenium natto powder, phytosterol powder, green-tea extract powder are combined together according to the ratio of science, from suppressing the formation of thrombus, the dissolving that increases thrombus, the acting in conjunction of enhancing vascular toughness three aspects:, effectively prevent the generation of cardiovascular and cerebrovascular disease.
Brief description of the drawings
Fig. 1 is that Zhang takes the blood vessel plaque detection result figure before the rich selenium natto product of the present invention.
Fig. 2 is that Zhang takes the blood vessel plaque detection result figure after the rich selenium natto product of the present invention.
Fig. 3 is that Zhang takes the blood vessel thickness testing result figure before the rich selenium natto product of the present invention.
Fig. 4 is that Zhang takes the blood vessel thickness testing result figure after the rich selenium natto product of the present invention.
Fig. 5 is that Chen takes the blood vessel plaque detection result figure before the rich selenium natto product of the present invention.
Fig. 6 is that Chen takes the blood vessel plaque detection result figure after the rich selenium natto product of the present invention.
Fig. 7 is that Guo takes the blood vessel plaque detection result figure before the rich selenium natto product of the present invention.
Fig. 8 is that Guo takes the blood vessel plaque detection result figure after the rich selenium natto product of the present invention.
Fig. 9 is that Guo takes the blood vessel thickness testing result figure before the rich selenium natto product of the present invention.
Figure 10 is that Guo takes the blood vessel thickness testing result figure after the rich selenium natto product of the present invention.
Figure 11 is that Lee takes the blood vessel plaque detection result figure before the rich selenium natto product of the present invention.
Figure 12 is that Lee takes the blood vessel plaque detection result figure after the rich selenium natto product of the present invention.
Detailed description of the invention
For the object, technical solutions and advantages of the present invention are better described, below in conjunction with specific embodiment, the invention will be further described.
Embodiment 1
The rich selenium natto product of an embodiment of the present invention, the component that described rich selenium natto product comprises following weight portion: 35 parts of rich selenium natto powders, 16 parts, phytosterol powder, 15 parts, green-tea extract powder.Described in the present embodiment, rich selenium natto product can be made into chewable tablets, capsule, 400mg/ sheet, edible 2～3 of every day; Or be made into pulvis solid beverage, every daily warm water Instant Drinks 1～2g.
Described in the present embodiment in rich selenium natto product, the activity that contains selenium Nattokinase in described rich selenium natto powder is 2000FU/g, Organic Selenium 60 μ g/g, in described phytosterol powder, contain phytosterol 110mg/g, in described green-tea extract powder, contain catechin 100mg/g.The Organic Selenium containing in described rich selenium natto powder mainly exists with the form of natural selenoprotein, selenoaminoacid, as selenomethionine, seleno methyl cysteine, is natural selenium polysaccharide on a small quantity.
Embodiment 2
The rich selenium natto product of an embodiment of the present invention, the component that described rich selenium natto product comprises following weight portion: 50 parts of rich selenium natto powders, 10 parts, phytosterol powder, 10 parts, green-tea extract powder, 5 parts of soybean lecithins, 7 parts of isomalts, 10 parts of starch, 2 parts of mannitols, 6 parts of lactose, 5 parts of dolomols.Described in the present embodiment, rich selenium natto product can be made into chewable tablets, capsule, 400mg/ sheet, edible 2～3 of every day; Or be made into pulvis solid beverage, every daily warm water Instant Drinks 1～2g.
Described in the present embodiment in rich selenium natto product, the activity that contains selenium Nattokinase in described rich selenium natto powder is 2200FU/g, Organic Selenium 50 μ g/g, in described phytosterol powder, contain phytosterol 100mg/g, in described green-tea extract powder, contain catechin 125mg/g.The Organic Selenium containing in described rich selenium natto powder mainly exists with the form of natural selenoprotein, selenoaminoacid, as selenomethionine, seleno methyl cysteine, is natural selenium polysaccharide on a small quantity.
Embodiment 3
The rich selenium natto product of an embodiment of the present invention, the component that described rich selenium natto product comprises following weight portion: 35 parts of rich selenium natto powders, 12 parts, phytosterol powder, 15 parts, green-tea extract powder, 9 parts of soybean lecithins, 4 parts of isomalts, 15 parts of starch, 1 part of mannitol, 5 parts of lactose.Described in the present embodiment, rich selenium natto product can be made into chewable tablets, capsule, 400mg/ sheet, edible 2～3 of every day; Or be made into pulvis solid beverage, every daily warm water Instant Drinks 1～2g.
Described in the present embodiment in rich selenium natto product, the activity that contains selenium Nattokinase in described rich selenium natto powder is 2300FU/g, Organic Selenium 70 μ g/g, in described phytosterol powder, contain phytosterol 125mg/g, in described green-tea extract powder, contain catechin 120mg/g.The Organic Selenium containing in described rich selenium natto powder mainly exists with the form of natural selenoprotein, selenoaminoacid, as selenomethionine, seleno methyl cysteine, is natural selenium polysaccharide on a small quantity.
Embodiment 4
The rich selenium natto product of an embodiment of the present invention, the component that described rich selenium natto product comprises following weight portion: 36 parts of rich selenium natto powders, 13 parts, phytosterol powder, 13 parts, green-tea extract powder, 12 parts of soybean lecithins, 2 parts of isomalts, 9 parts of mannitols, 10 parts of dolomols.Described in the present embodiment, rich selenium natto product can be made into chewable tablets, capsule, 400mg/ sheet, edible 2～3 of every day; Or be made into pulvis solid beverage, every daily warm water Instant Drinks 1～2g.
Described in the present embodiment in rich selenium natto product, the activity that contains selenium Nattokinase in described rich selenium natto powder is 2500FU/g, Organic Selenium 87.5 μ g/g, in described phytosterol powder, contain phytosterol 120mg/g, in described green-tea extract powder, contain catechin 105mg/g.The Organic Selenium containing in described rich selenium natto powder mainly exists with the form of natural selenoprotein, selenoaminoacid, as selenomethionine, seleno methyl cysteine, is natural selenium polysaccharide on a small quantity.
Embodiment 5
The rich selenium natto product of an embodiment of the present invention, the component that described rich selenium natto product comprises following weight portion: 38 parts of rich selenium natto powders, 14 parts, phytosterol powder, 12 parts, green-tea extract powder, 32 parts of starch.Described in the present embodiment, rich selenium natto product can be made into chewable tablets, capsule, 400mg/ sheet, edible 2～3 of every day; Or be made into pulvis solid beverage, every daily warm water Instant Drinks 1～2g.
Described in the present embodiment in rich selenium natto product, the activity that contains selenium Nattokinase in described rich selenium natto powder is 2200FU/g, Organic Selenium 50 μ g/g, in described phytosterol powder, contain phytosterol 100mg/g, in described green-tea extract powder, contain catechin 125mg/g.The Organic Selenium containing in described rich selenium natto powder mainly exists with the form of natural selenoprotein, selenoaminoacid, as selenomethionine, seleno methyl cysteine, is natural selenium polysaccharide on a small quantity.
Embodiment 6
The rich selenium natto product of an embodiment of the present invention, the component that described rich selenium natto product comprises following weight portion: 45 parts of rich selenium natto powders, 15 parts, phytosterol powder, 11 parts, green-tea extract powder, 15 parts of soybean lecithins, 20 parts of lactose.Described in the present embodiment, rich selenium natto product can be made into chewable tablets, capsule, 400mg/ sheet, edible 2～3 of every day; Or be made into pulvis solid beverage, every daily warm water Instant Drinks 1～2g.
Described in the present embodiment in rich selenium natto product, the activity that contains selenium Nattokinase in described rich selenium natto powder is 2400FU/g, Organic Selenium 75 μ g/g, in described phytosterol powder, contain phytosterol 105mg/g, in described green-tea extract powder, contain catechin 120mg/g.The Organic Selenium containing in described rich selenium natto powder mainly exists with the form of natural selenoprotein, selenoaminoacid, as selenomethionine, seleno methyl cysteine, is natural selenium polysaccharide on a small quantity.
Embodiment 7
Zhang, man, 63 years old, take the rich selenium natto product of the present invention according to the method described in embodiment 1-6 and dosage, take three months, employing colorful Doppler ultrasound diagnostic apparatus detects this patient's arteria carotis, mainly detects patient's the interior patch of blood vessel, endangium thickness and blood flow state.This patient is taking before rich selenium natto product of the present invention, and this patient vessel's inwall patch is obvious, Patch size be 0.77cm × 0.20cm(as shown in Figure 1); Take the rich selenium natto product of the present invention after three months, this patient vessel's inwall patch obviously reduces, and patch is reduced to 0.30cm × 0.13cm(as shown in Figure 2).This patient is taking before the rich selenium natto product of the present invention, its blood vessel thickness thicker (as shown in Figure 3), take the rich selenium natto product of the present invention after three months, this patient's blood vessel thickness obviously reduces, vascular wall caliper recovery normal (as shown in Figure 4).This patient takes before rich selenium natto product of the present invention, and the situation of cutout and eddy current appears in its blood flow state, and takes the rich selenium natto product of the present invention after three months, and it is normal that VPV recovers.This patient took rich selenium natto product of the present invention after three months, and original cardiovascular and cerebrovascular abnormality greatly alleviates, and patient feels that health is good, and especially the cardiovascular and cerebrovascular abnormality such as numbness in hands and feet, asthma uncomfortable in chest, brain vigor deficiency disappears.
Embodiment 8
Chen, 87 years old, man, took the rich selenium natto product of the present invention according to the method described in embodiment 1-6 and dosage, takes four months, adopts colorful Doppler ultrasound diagnostic apparatus to detect before and after taking, and finds that the intracarotid patch of this patient obviously dwindles.This patient take before the rich selenium natto product of the present invention blood vessel Patch size be 2.86cm × 0.22cm(as shown in Figure 5), and take the rich selenium natto product of the present invention after four months, its blood vessel Patch size be 1.55cm × 0.17cm(as shown in Figure 6).In addition, this patient is taking after the rich selenium natto product of the present invention, and its blood drag index declines, and frequency spectrum is not when taking before four months, and more regular, overall blood flow obviously improves.
Embodiment 9
Guo, 82 years old, man, took the rich selenium natto product of the present invention according to the method described in embodiment 1-6 and dosage, takes four months, and its blood drag index declines, and frequency spectrum is not when taking before four months, and more regular, obvious eddy current reduces, and blood engorgement degree improves.This patient takes before the rich selenium natto product of the present invention, blood vessel Patch size be 0.58cm × 0.26cm(as shown in Figure 7), take the rich selenium natto product of the present invention after four months, blood vessel Patch size be 0.21cm × 0.18cm(as shown in Figure 8), thrombus patch obviously dwindles.This patient is taking before the rich selenium natto product of the present invention, its blood vessel thickness thicker (as shown in Figure 9), take the rich selenium natto product of the present invention after four months, this patient's blood vessel thickness obviously reduces, vascular wall caliper recovery normal (as shown in Figure 10).
Embodiment 10
Lee, 76 years old, female, take the rich selenium natto product of the present invention according to the method described in embodiment 1-6 and dosage, take four months, before and after taking, detect respectively with colorful Doppler ultrasound diagnostic apparatus, after the rich selenium natto product of the present invention is taken in discovery, local blood fullness degree obviously improves, and cutout situation disappears.This patient takes before the rich selenium natto product of the present invention, blood vessel Patch size be 1.31cm × 0.23cm(as shown in Figure 11), take the rich selenium natto product of the present invention after four months, blood vessel Patch size be 0.29m × 0.17cm(as shown in Figure 12), thrombus patch significantly dwindles.
Embodiment 11
Lee, 56 years old, man, took the rich selenium natto product of the present invention according to the method described in embodiment 1-6 and dosage, takes four months, and before and after taking, physical examination result is as follows:
| Health check-up project | Before taking (mmol/l) | After taking (mmol/l) |
| T-CHOL | 6.3 | 4.3 |
| HDL-C | 1.7 | 1.12 |
| LDL-C | 2.03 | 3.4 |
In addition, this patient took the rich selenium natto product of the present invention after four months, and uncomfortable in chest, the phenomenon of breathing hard that after light exercise, just occur are greatly improved before.
Can be found out by embodiment 7-11, the rich selenium natto product of the present invention can, from suppressing dissolving, the acting in conjunction of enhancing vascular toughness three aspects: of thrombosis, increase thrombus, effectively prevent the generation of cardiovascular and cerebrovascular disease.
Last institute should be noted that; above embodiment is only in order to illustrate technical scheme of the present invention but not limiting the scope of the invention; although the present invention is explained in detail with reference to preferred embodiment; those of ordinary skill in the art is to be understood that; can modify or be equal to replacement technical scheme of the present invention, and not depart from essence and the scope of technical solution of the present invention.
Claims (9)
1. a rich selenium natto product, is characterized in that, the component that comprises following weight portion: 35～50 parts of rich selenium natto powders, 10～16 parts, phytosterol powder, 10～15 parts, green-tea extract powder;
Described rich selenium natto powder adopts following methods to be prepared from:
(1) actication of culture: activation medium is containing yeast extract, peptone, dipotassium hydrogen phosphate, sodium chloride, agar and distilled water, the pH of activation medium is 7.0～7.5, by culture medium at 119～121 DEG C after sterilizing 30min, inoculation bafillus natto, and be, at 36～38 DEG C, bafillus natto is activated to 24h in temperature;
(2) bacterial classification expands cultivation: the culture medium that bacterial classification expands contains peptone, glucose, dipotassium hydrogen phosphate, magnesium sulfate, calcium chloride and distilled water, the pH of culture medium is 7.0～7.5, by culture medium sterilizing 30min at 119～121 DEG C, be then at 36～38 DEG C, to expand to cultivate 24h by the bafillus natto after activation in temperature;
(3) fermentation: Drinking Water is heated to 50～60 DEG C, add rich selenium soyabean protein powder according to 10～15% of the water yield, fully stir and form rich selenium soyabean protein powder suspension, then in rich selenium soyabean protein powder suspension, add dipotassium hydrogen phosphate, regulating pH is 7.0～7.5, cooling after sterilizing 30min at 119～121 DEG C, add step (2) to expand the bafillus natto after cultivating, at 36～38 DEG C of bottom fermentation 48h;
(4) by the zymotic fluid after step (3) fermentation at 80～85 DEG C of deactivation 35min, after then at 60～70 DEG C, vacuum drying to solid content is 30%, freeze drying, obtains rich selenium natto powder.
2. rich selenium natto product as claimed in claim 1, is characterized in that the component that comprises following weight portion: 35～45 parts of rich selenium natto powders, 12～15 parts, phytosterol powder, 11～15 parts, green-tea extract powder.
3. rich selenium natto product as claimed in claim 2, is characterized in that the component that comprises following weight portion: 36～38 parts of rich selenium natto powders, 13～14 parts, phytosterol powder, 12～13 parts, green-tea extract powder.
4. rich selenium natto product as claimed in claim 1, is characterized in that, described rich selenium natto product also comprises the auxiliary material of 32～35 weight portions.
5. rich selenium natto product as claimed in claim 4, is characterized in that, described auxiliary material comprises at least one in soybean lecithin, isomalt, starch, mannitol, lactose, dolomol.
6. rich selenium natto product as claimed in claim 1, is characterized in that, contains Organic Selenium 50～87.5 μ g/g, selenium Nattokinase 2000～2500FU/g in described rich selenium natto powder; In described phytosterol powder, contain phytosterol 100～125mg/g; In described green-tea extract powder, contain catechin 100～125mg/g.
7. rich selenium natto product as claimed in claim 6, is characterized in that, described Organic Selenium is selenoprotein, selenoaminoacid, selenium polysaccharide.
8. rich selenium natto product as claimed in claim 1, is characterized in that, described rich selenium natto product is tablet, capsule or pulvis.
One kind as claimed in claim 1 rich selenium natto product for the preparation of prevention or treatment cardiovascular and cerebrovascular disease medicine in purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310158684.3A CN103230478B (en) | 2013-05-02 | 2013-05-02 | Selenium-rich natto product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310158684.3A CN103230478B (en) | 2013-05-02 | 2013-05-02 | Selenium-rich natto product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103230478A CN103230478A (en) | 2013-08-07 |
| CN103230478B true CN103230478B (en) | 2014-12-03 |
Family
ID=48878593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310158684.3A Active CN103230478B (en) | 2013-05-02 | 2013-05-02 | Selenium-rich natto product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103230478B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104256407B (en) * | 2014-10-09 | 2017-12-26 | 南京农业大学 | A kind of feature Chewable Tablets and its production technology |
| CN105054076B (en) * | 2015-08-25 | 2017-09-19 | 广州金酮医疗科技有限公司 | A kind of alimentation composition and its application for helping to improve alzheimer's disease |
| CN105998726A (en) * | 2016-05-20 | 2016-10-12 | 王思烨 | Natto protein powder |
| CN106889410B (en) * | 2017-01-17 | 2021-01-08 | 陕西宏梁食品科技有限公司 | High-viable-bacteria natto solid beverage and preparation method thereof |
| CN106954797A (en) * | 2017-03-11 | 2017-07-18 | 北京中科卓尔生物科技有限公司 | Polypeptide natto powder and preparation method thereof |
| CN106820127A (en) * | 2017-03-11 | 2017-06-13 | 北京中科卓尔生物科技有限公司 | Selenium-rich natto fine powder and preparation method thereof |
| CN106942608A (en) * | 2017-03-11 | 2017-07-14 | 北京中科卓尔生物科技有限公司 | Natto fine powder and preparation method thereof |
| CN107094902A (en) * | 2017-04-26 | 2017-08-29 | 合肥华创现代农业科技有限公司 | Bean product and preparation method thereof |
| CN107125326A (en) * | 2017-04-26 | 2017-09-05 | 合肥华创现代农业科技有限公司 | Bean food and preparation method thereof |
| CN110897164A (en) * | 2019-12-26 | 2020-03-24 | 广州莱可福生物科技有限公司 | Composition containing phytosterol and application of composition in improving blood sugar |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101444273B (en) * | 2007-11-22 | 2013-04-24 | 何煜 | Health product oral fast-release preparation and production method thereof |
| CN101791011A (en) * | 2009-12-31 | 2010-08-04 | 苏州硒谷科技有限公司 | Production method of selenium-enriched soybean flour |
| CN102872306B (en) * | 2012-09-25 | 2014-04-09 | 深圳市安美信生物医药科技有限公司 | Compound selenium Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof |
-
2013
- 2013-05-02 CN CN201310158684.3A patent/CN103230478B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103230478A (en) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103230478B (en) | Selenium-rich natto product | |
| CN104473249B (en) | A kind of liquid preparation of Pollen Pini and preparation method thereof | |
| TWI516280B (en) | Use of chenopodium formosanum extract for manufacture of composition for enhancing secretion of collagen and preventing cutaneous aging | |
| CN102224891A (en) | Sugar alcohol honey apple jam and preparation method thereof | |
| CN104107424A (en) | Qi cultivating thrombolytic medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN107019211A (en) | Prepare the fermentation composition and preparation method of the plant enzyme with the strong renal function of kidney tonifying | |
| CN104222407A (en) | Wild chrysanthemum tea health beverage | |
| KR20140040611A (en) | Extract of smilax china leaf with aspergillus species, method for preparing the same and use of the same | |
| CN107252095A (en) | composite enzyme and preparation method thereof | |
| CN107050073A (en) | It is a kind of to strengthen memory, the health products for slowing down brain aging and preparation method thereof | |
| KR20240011214A (en) | Composition for treating or preventing metabolic disease | |
| CN106880040A (en) | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients | |
| CN105998726A (en) | Natto protein powder | |
| JP2010100663A (en) | Enzyme inhibitor containing fermentation product of allium cepa l | |
| JP2005097222A (en) | Fermented product of allium cepa l. | |
| CN107047864A (en) | Chronic pharyngitis conditioning health protection tea and preparation method thereof | |
| CN103798667B (en) | Bacterium congo red jujube haw jelly and preparation method thereof | |
| CN106729675A (en) | It is a kind of to treat pharmaceutical composition of cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN109645295A (en) | A kind of Astaxanthin In Haematococcus Pluvialis solid beverage maintaining cardiovascular system health | |
| KR100994196B1 (en) | Method of preparing fermented liquid of garlic and chonggugjang | |
| KR20180108515A (en) | Composition for improving sleep disturbance and preparation method thereof | |
| CN103584226B (en) | Heat clearing and internal heat decreasing beverage and preparation method thereof | |
| CN104206582A (en) | Aquilaria sinensis leaf tea drink and preparation technology thereof | |
| TWI337541B (en) | A composition comprising lactobacillus sp. pm308 composition for treating obesity, ameliorating endomorph body type, decreasing body fat ratio and reducing cholesterol | |
| CN101530210B (en) | Health preserving wine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU HONGTAI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20141031 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510630 GUANGZHOU, GUANGDONG PROVINCE TO: 510530 GUANGZHOU, GUANGDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20141031 Address after: 510530 Guangdong province high tech Industrial Development Zone, Science City, Kaiyuan Avenue, building, floor 11, C1, Fifth Applicant after: GUANGZHOU CINJEP BIOTECHNOLOGY Co.,Ltd. Applicant after: GUANGZHOU HTIDE MEDICAL TECHNOLOGY Co.,Ltd. Address before: 510630 first floor, No. 20 middle road, Tianhe hi tech Industrial Park, Guangdong, Guangzhou Applicant before: GUANGZHOU CINJEP BIOTECHNOLOGY Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: GUANGZHOU HONGTAI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150805 Owner name: TONGTAI MYOCARDIAL AND CEREBRAL HEALTH MANAGEMENT Free format text: FORMER OWNER: GUANGZHOU CINJEP BIOTECHNOLOGY CO., LTD. Effective date: 20150805 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150805 Address after: 309, room 11, 510630 software Road, Guangdong, Guangzhou, Tianhe District Patentee after: TUNETAI HEART AND BRAIN HEALTH MANAGEMENT Co.,Ltd. Address before: 510530 Guangdong province high tech Industrial Development Zone, Science City, Kaiyuan Avenue, building, floor 11, C1, Fifth Patentee before: GUANGZHOU CINJEP BIOTECHNOLOGY Co.,Ltd. Patentee before: GUANGZHOU HTIDE MEDICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190116 Address after: 510000 Room 303, 3/F, No. 11 Software Road, Tianhe Software Park, Tianhe District, Guangzhou City, Guangdong Province (This residence is for office use only) Patentee after: GUANGZHOU KETO MEDICAL TECHNOLOGY Co.,Ltd. Address before: Room 309, No. 11 Software Road, Tianhe District, Guangzhou City, Guangdong Province Patentee before: TUNETAI HEART AND BRAIN HEALTH MANAGEMENT Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191210 Address after: 510000, C1 building, No. 11, Kaiyuan Avenue, Science City, Guangzhou hi tech Industrial Development Zone, Guangdong, Fifth Patentee after: Guangzhou Jin Tong special medicals Food Co.,Ltd. Address before: 510000 Room 303, 3/F, No. 11 Software Road, Tianhe Software Park, Tianhe District, Guangzhou City, Guangdong Province (This residence is for office use only) Patentee before: GUANGZHOU KETO MEDICAL TECHNOLOGY Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Selenium-rich natto product Effective date of registration: 20200610 Granted publication date: 20141203 Pledgee: Senbao Branch of Guangzhou Bank Co.,Ltd. Pledgor: Guangzhou Jin Tong special medicals Food Co.,Ltd. Registration number: Y2020440000132 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210903 Granted publication date: 20141203 Pledgee: Senbao Branch of Guangzhou Bank Co.,Ltd. Pledgor: Guangzhou Jin Tong special medicals Food Co.,Ltd. Registration number: Y2020440000132 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Selenium enriched natto product Effective date of registration: 20210910 Granted publication date: 20141203 Pledgee: Tianhe sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Jin Tong special medicals Food Co.,Ltd. Registration number: Y2021980009192 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221230 Granted publication date: 20141203 Pledgee: Tianhe sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Jin Tong special medicals Food Co.,Ltd. Registration number: Y2021980009192 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |